Alterations in the red blood cell membrane proteome in alzheimer's subjects reflect disease-related changes and provide insight into altered cell morphology

Table 3 Personal and medication data of AD (A1-A5) and control (C1-C5) subjects used in this study:

Subject	Gender	Age	Medications taken
A1	Female	81	ESTRGN
A2	Female	84	ACED, NTCA, THRY, HTNMED
A3	Male	89	ASA
A4	Male	99	ADPI, ASA, HCTZ
A5	Male	85	ALZH
C1	Female	83	ASA, BETA, LOOP, DIUR, HTNMED
C2	Female	91	ASA, COX2, THRY
C3	Male	87	ASA, DLTIR, NSAID, CCBIR, CCB, HTNMED
C4	Male	87	HCTZ, PPI, DIUR, HTNMED
C5	Male	85	None

N.B. Medication abbreviations are ACED (Ace inhibitors with diuretics), ADPI (Inhibitors of ADP-induced platelet aggregation), ALZH (Acetylcholine esterase inhibitors for AD), ASA (Aspirin), BETA (Beta-blockers without diuretics), CCB (Any Calcium-channel blocker = CCIR OR CCBSR OR CCBT), CCBIR (Immediate-release CCBS = NIFIR OR DIHIR OR VERIR OR DLTIR), CCBT (T-type Calcium-channel blocker), COX2 (COX-2 inhibitors (NSAID Agents); separate from NSAID variable), DIHIR (Immediate-release Dihydropyridines other than Nifedipine), DIUR (Any diuretic), DLTIR (Immediate-release Diltiazem), ESTRGN (Estrogens, excluding vaginal creams), HCTZ (Thiazide diuretics without K-sparing agents), HTNMED (Any anti-hypertensive medication), LOOP (Loop diuretics), NIFIR (Immediate-release Nifedipine), NSAID (Non-steroidal anti-inflammatory agents, excluding Aspirin), NTCA (Non-tricyclic antidepressants other than MAO Inhibitors), PPI (Proton pump inhibitors), THRY (Thyroid agents), VERIR (Immediate-release Verapamil),

ISSN: 1477-5956